 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

- $6.85 million upfront investment provides $23 million total cash runway into second half 2025 - - Financing allows for focused commercial team to bring Femasys' infertility-related products to...

Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

PharmaCyte Biotech makes $5M investment in Femasys to utilize cash position

PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (PharmaCyte or the Company) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (Femasys), a biomedical company focused on meeting...

PharmaCyte Biotech Acquires $5 Million Stake in Emerging Womens Health Innovator Femasys, Inc.

PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (PharmaCyte or the Company) provides an update on its investigation of its Cell-in-a-Box technology and initial next steps in development. Following a...

PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology

PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (PharmaCyte or the Company) today announces the final results of its previously announced tender offer to acquire up to 7,750,000 million shares of the Companys common stock, par value $0.001 per share, at a price of $3.25 per share in cash, less any...

PharmaCyte Biotech Announces Final Results of Tender Offer

PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (PharmaCyte or the Company) today announces a cash tender offer for up to 7,750,000 shares at $3.25 per share, less any applicable withholding taxes and without interest. The Company also announces that it has completed a private placement financing of...

PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share

Topics to Include Continued Analysis of FDAs Clinical Holdon IND for Cell-in-a-BoxLAS VEGAS, Oct. 07, 2022 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (PharmaCyte or the Company), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Cell-in-a...

PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that PharmaCyte and Iroquois Master Fund Ltd. and its...

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Las Vegas, NV.

Watchers	5,976
52-Wk Low	$1.92
52-Wk High	$3.23

Market Cap	$20.1M
Volume (M)	5.00
52-Wk High	$3.23
52-Wk Low	$1.92

PMCB PharmaCyte Biotech Inc

About

Feed

News

Earnings

Fundamentals